Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2012-02, Vol.14 (1), p.R33-R33, Article R33
Hauptverfasser:	Ginzler, Ellen M, Wax, Stephen, Rajeswaran, Anand, Copt, Samuel, Hillson, Jan, Ramos, Eleanor, Singer, Nora G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Adult Care and treatment Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Humans Immunoglobulin G - blood Infection - chemically induced Lupus Nephritis - blood Lupus Nephritis - drug therapy Male Middle Aged Mycophenolic Acid - adverse effects Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Nephritis Patient outcomes Prednisone - adverse effects Prednisone - therapeutic use Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!